专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09090712B2 Diagnosis of carcinomas 有权
公开(公告)号：US09090712B2
公开(公告)日：2015-07-28
申请号：US12536975
申请日：2009-08-06
申请人： Ingegerd Hellstrom , Jeffrey A. Ledbetter , Martha Hayden-Ledbetter
发明人： Ingegerd Hellstrom , Jeffrey A. Ledbetter , Martha Hayden-Ledbetter
IPC分类号： C07K14/435 , C07K19/00 , C07K14/81 , C07K16/18 , C07K16/30 , C07K16/40 , G01N33/574 , G01N33/53 , A61K39/00
CPC分类号： G01N33/57449 , A61K2039/505 , C07K14/811 , C07K16/18 , C07K16/30 , C07K16/3069 , C07K16/40 , C07K2319/00 , C07K2319/30 , G01N33/57488 , G01N2333/705
摘要： The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble and cell surface forms of HE4a polypeptides, including HE4a that is overexpressed in ovarian carcinomas. In particular the invention provides a nucleic acid sequence encoding HE4a, and also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a HE4a polypeptide with a molecule naturally occurring in soluble and/or cell surface form in a sample from such a subject, and by hybridization screening using an HE4a nucleotide sequence, as well as other related advantages.

2. 发明申请

US20100034820A1 BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS 有权
标题翻译：结合域 - 免疫球蛋白融合蛋白
公开(公告)号：US20100034820A1
公开(公告)日：2010-02-11
申请号：US12541062
申请日：2009-08-13
申请人： Jeffrey A. Ledbetter , Martha Hayden-Ledbetter , Peter A. Thompson
发明人： Jeffrey A. Ledbetter , Martha Hayden-Ledbetter , Peter A. Thompson
IPC分类号： A61K39/395 , C07K16/00
CPC分类号： C07K16/3061 , A61K38/00 , A61K39/0011 , A61K2039/505 , A61K2039/5152 , A61K2039/5156 , A61K2039/5158 , C07K16/2809 , C07K16/2818 , C07K16/2878 , C07K16/2896 , C07K16/462 , C07K2317/22 , C07K2317/24 , C07K2317/53 , C07K2317/622 , C07K2317/64 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/30 , C12N5/0636 , C12N2501/23 , C12N2501/51 , C12N2501/515 , C12N2501/52 , C12N2502/11 , C12N2510/00
摘要： The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IGA or IgE hinge region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high express levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.
摘要翻译：本发明涉及新颖的结合域 - 免疫球蛋白融合蛋白，其特征在于用于诸如抗原，反向受体等的同源结构的结合结构域，野生型IgG1，IGA或IgE铰链区多肽或突变IgG1铰链区多肽具有零个，一个或两个半胱氨酸残基，以及免疫球蛋白CH2和CH3结构域，并且它们能够以ADCC和/或CDC的形式发生，同时主要作为其形成二硫键连接的多聚体的能力被损害的多肽。融合蛋白可以以高表达水平重组产生。还提供了相关的组合物和方法，包括融合蛋白的细胞表面形式和融合蛋白的免疫治疗应用以及编码这种融合蛋白的多核苷酸。

3. 发明申请

US20090104684A1 Diagnosis of carcinomas 审中-公开
标题翻译：诊断癌
公开(公告)号：US20090104684A1
公开(公告)日：2009-04-23
申请号：US11890896
申请日：2007-08-08
申请人： Michel Schummer , INGEGERD HELLSTROM , Karl Erik Hellstrom , JEFFREY A. LEDBETTER , MARTHA HAYDEN-LEDBETTER
发明人： Michel Schummer , INGEGERD HELLSTROM , Karl Erik Hellstrom , JEFFREY A. LEDBETTER , MARTHA HAYDEN-LEDBETTER
IPC分类号： C12N1/16 , C07K16/00
CPC分类号： G01N33/57449 , A61K2039/505 , C07K14/811 , C07K16/18 , C07K16/30 , C07K16/3069 , C07K16/40 , C07K2319/00 , C07K2319/30 , G01N33/57488 , G01N2333/705
摘要： The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble and cell surface forms of HE4a polypeptides, including HE4a that is overexpressed in ovarian carcinomas. In particular the invention provides a nucleic acid sequence encoding HE4a, and also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a HE4a polypeptide with a molecule naturally occurring in soluble and/or cell surface form in a sample from such a subject, and by hybridization screening using an HE4a nucleotide sequence, as well as other related advantages.
摘要翻译：本发明涉及用于检测恶性病症的组合物和方法，并且涉及HE4a多肽的可溶性和细胞表面形式的发现，包括在卵巢癌中过表达的HE4a。特别地，本发明提供了编码HE4a的核酸序列，并且还提供了通过检测对具有天然存在于可溶性和/或可溶性的分子的HE4a多肽的特异性抗体的反应性来筛选受试者中恶性病症的存在的方法。来自这样的受试者的样品中的细胞表面形式，以及使用HE4a核苷酸序列的杂交筛选以及其它相关优点。

4. 发明授权

US07270960B2 Diagnosis of ovarian carcinomas 有权
标题翻译：诊断卵巢癌
公开(公告)号：US07270960B2
公开(公告)日：2007-09-18
申请号：US10233150
申请日：2002-08-28
申请人： Ingegerd Hellstrom , Jeffrey A. Ledbetter , Martha Hayden-Ledbetter
发明人： Ingegerd Hellstrom , Jeffrey A. Ledbetter , Martha Hayden-Ledbetter
IPC分类号： G01N33/48 , G01N33/50 , G01N33/53
CPC分类号： G01N33/57449 , A61K2039/505 , C07K14/811 , C07K16/18 , C07K16/30 , C07K16/3069 , C07K16/40 , C07K2319/00 , C07K2319/30 , G01N33/57488 , G01N2333/705
摘要： The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble and cell surface forms of HE4a polypeptides, including HE4a that is overexpressed in ovarian carcinomas. In particular the invention provides a nucleic acid sequence encoding HE4a, and also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a HE4a polypeptide with a molecule naturally occurring in soluble and/or cell surface form in a sample from such a subject, and by hybridization screening using an HE4a nucleotide sequence, as well as other related advantages.
摘要翻译：本发明涉及用于检测恶性病症的组合物和方法，并且涉及HE4a多肽的可溶性和细胞表面形式的发现，包括在卵巢癌中过表达的HE4a。特别地，本发明提供了编码HE4a的核酸序列，并且还提供了通过检测对具有天然存在于可溶性和/或可溶性的分子的HE4a多肽的特异性抗体的反应性来筛选受试者中恶性病症的存在的方法。来自这样的受试者的样品中的细胞表面形式，以及使用HE4a核苷酸序列的杂交筛选以及其它相关优点。

5. 发明申请

US20070059306A1 B-cell reduction using CD37-specific and CD20-specific binding molecules 审中-公开
标题翻译：使用CD37特异性和CD20特异性结合分子的B细胞减少
公开(公告)号：US20070059306A1
公开(公告)日：2007-03-15
申请号：US11493132
申请日：2006-07-25
申请人： Laura Grosmaire , Martha Hayden-Ledbetter , Jeffrey Ledbetter , Peter Thompson , Sandy Simon , William Brady
发明人： Laura Grosmaire , Martha Hayden-Ledbetter , Jeffrey Ledbetter , Peter Thompson , Sandy Simon , William Brady
IPC分类号： A61K39/395
CPC分类号： A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K16/2887 , C07K16/2896 , C07K16/30 , C07K16/3061 , C07K2317/24 , C07K2317/52 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/72 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/75 , C07K2317/76 , A61K2300/00
摘要： The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.
摘要翻译：本发明通常提供使用CD37特异性结合分子的个体中B细胞减少的方法。特别地，本发明提供了使用单独的CD37-特异性结合分子或CD37-特异性结合分子和CD20-特异性结合分子的组合（在某些情况下是协同组合）的B细胞减少的方法。本发明还提供了用于治疗涉及异常B细胞活性的疾病的材料和方法。此外，本发明提供了人源化的CD37特异性结合分子。

6. 发明授权

US07118751B1 DNA vaccines encoding antigen linked to a domain that binds CD40 失效
标题翻译：编码与结合CD40的结构域连接的抗原的DNA疫苗
公开(公告)号：US07118751B1
公开(公告)日：2006-10-10
申请号：US09687864
申请日：2000-10-13
申请人： Jeffrey A Ledbetter , Martha Hayden-Ledbetter
发明人： Jeffrey A Ledbetter , Martha Hayden-Ledbetter
IPC分类号： A61K39/00
CPC分类号： C07K14/005 , A61K39/00 , A61K39/12 , A61K39/21 , A61K2039/53 , A61K2039/57 , A61K2039/6031 , C07K2319/00 , C12N2740/16122 , C12N2740/16134
摘要： Vaccines that target one or more antigens to a cell surface receptor improve the antigen-specific humoral and cellular immune response. Antigen(s) linked to a domain that binds to a cell surface receptor are internalized, carrying antigen(s) into an intracellular compartment where the antigen(s) are digested into peptides and loaded onto MHC molecules. T cells specific for the peptide antigens are activated, leading to an enhanced immune response. The vaccine may comprise antigen(s) linked to a domain that binds at least one receptor or a DNA plasmid encoding antigen(s) linked to a domain that binds at least one receptor. A preferred embodiment of the invention targets HIV-1 env antigen to the CD40 receptor, resulting in delivery of antigen to CD40 positive cells, and selective activation of the CD40 receptor on cells presenting HIV-1 env antigens to T cells.
摘要翻译：将一种或多种抗原靶向细胞表面受体的疫苗可改善抗原特异性体液和细胞免疫应答。与结合细胞表面受体的结构域连接的抗原被内化，将抗原携带到细胞内隔室中，其中抗原被消化成肽并加载到MHC分子上。对肽抗原特异性的T细胞被激活，导致增强的免疫应答。疫苗可以包含连接到结合至少一种受体的结构域的抗原或编码与结合至少一种受体的结构域连接的抗原的DNA质粒。本发明的优选实施方案将HIV-1 env抗原靶向CD40受体，导致抗原递送至CD40阳性细胞，以及将呈递HIV-1 env抗原的细胞上的CD40受体选择性激活至T细胞。

7. 发明申请

US20050238646A1 Binding domain-immunoglobulin fusion proteins 审中-公开
公开(公告)号：US20050238646A1
公开(公告)日：2005-10-27
申请号：US11089368
申请日：2005-03-23
申请人： Jeffrey Ledbetter , Martha Hayden-Ledbetter
发明人： Jeffrey Ledbetter , Martha Hayden-Ledbetter
IPC分类号： C07K16/28 , C07K16/46 , A61K39/395
CPC分类号： C07K16/46 , A61K2039/505 , C07K16/2809 , C07K16/2818 , C07K16/2878 , C07K16/2896 , C07K16/462 , C07K2317/22 , C07K2317/24 , C07K2317/53 , C07K2317/622 , C07K2317/64 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/30
摘要： The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.

8. 发明申请

US20050202012A1 Binding domain-immunogloubulin fusion proteins 审中-公开
标题翻译：结合域免疫组蛋白融合蛋白
公开(公告)号：US20050202012A1
公开(公告)日：2005-09-15
申请号：US11088737
申请日：2005-03-23
申请人： Jeffrey Ledbetter , Martha Hayden-Ledbetter
发明人： Jeffrey Ledbetter , Martha Hayden-Ledbetter
IPC分类号： C07K16/28 , C07K16/46 , A61K39/395
CPC分类号： C07K16/46 , A61K2039/505 , C07K16/2809 , C07K16/2818 , C07K16/2878 , C07K16/2896 , C07K16/462 , C07K2317/22 , C07K2317/24 , C07K2317/53 , C07K2317/622 , C07K2317/64 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/30
摘要： The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.
摘要翻译：本发明涉及新颖的结合域 - 免疫球蛋白融合蛋白，其特征在于同源结构如结合抗原，反式受体等的结合结构域，具有零个或一个半胱氨酸残基的铰链区多肽和免疫球蛋白CH2和CH3结构域，并且其能够主要以单体多肽的形式存在于ADCC和/或CDC。可以以高表达水平重组产生融合蛋白。还提供了相关的组合物和方法，包括免疫治疗应用。

9. 发明申请

US20050180970A1 Binding domain-immunoglobulin fusion proteins 审中-公开
公开(公告)号：US20050180970A1
公开(公告)日：2005-08-18
申请号：US11089190
申请日：2005-03-23
申请人： Jeffrey Ledbetter , Martha Hayden-Ledbetter
发明人： Jeffrey Ledbetter , Martha Hayden-Ledbetter
IPC分类号： C07K16/28 , C07K16/46 , A61K39/395 , C12P21/04
CPC分类号： C07K16/46 , A61K2039/505 , C07K16/2809 , C07K16/2818 , C07K16/2878 , C07K16/2896 , C07K16/462 , C07K2317/22 , C07K2317/24 , C07K2317/53 , C07K2317/622 , C07K2317/64 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/30
摘要： The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.

10. 发明申请

US20140044711A1 Therapeutic Nuclease Compositions and Methods 审中-公开
标题翻译：治疗性核酸酶组合物和方法
公开(公告)号：US20140044711A1
公开(公告)日：2014-02-13
申请号：US13822215
申请日：2012-04-27
申请人： Jeffrey A. Ledbetter , Martha Hayden-Ledbetter , Keith Elkon , Xizhang Sun
发明人： Jeffrey A. Ledbetter , Martha Hayden-Ledbetter , Keith Elkon , Xizhang Sun
IPC分类号： C12N9/22 , C07K16/46
CPC分类号： C12N9/22 , A61K38/465 , A61K47/68 , A61K47/6815 , C07K16/44 , C07K2319/30 , C12Y301/27005
摘要： Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.
摘要翻译：杂交核酸酶分子和用于治疗哺乳动物免疫相关疾病或病症的方法和用于治疗哺乳动物免疫相关疾病的药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式